COVID-19

Tonix Pharmaceuticals to Participate in the 2024 BIO CEO & Investor Conference

CHATHAM, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical…

11 months ago

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic

BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) --  TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively…

11 months ago

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD

COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio…

11 months ago

RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

- RAPT to host a conference call today at 8:30 am ET - SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024…

11 months ago

BioCryst Launches ORLADEYO® (berotralstat) in Italy

RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Italian Medicines…

11 months ago

Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds

EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial…

11 months ago

AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million

Portfolio optimization enhances strategic focus and follows initiative to restructure manufacturing footprint Company to discontinue sales of radiofrequency ablation and…

11 months ago

NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury

On track to complete enrollment of the chronic cohort in Q2 2024Data readout from chronic cohort expected in Q3 2024Planning…

11 months ago

NanoViricides Has Filed its Quarterly Report – NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon

SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum…

11 months ago